Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511029 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)
A Phase 1 study, sponsored by Knopp Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT01511029 is a Phase 1 study that has completed, run by Knopp Biosciences. The registered enrollment target is 68 participants.
The verdict
NCT01511029, a Phase 1 study, has completed, sponsored by Knopp Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers.
Interventions
- DRUG Moxifloxacin
- DRUG Dexpramipexole
- DRUG Dexpramipexole Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01511029
The ClinicalTrials.gov registry entry for NCT01511029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Knopp Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT01511029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01511029 about?
NCT01511029 is a clinical study titled "Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)". To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers.
What is the current status of trial NCT01511029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2012-01. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01511029?
The interventions under investigation include: Moxifloxacin (DRUG), Dexpramipexole (DRUG), Dexpramipexole Placebo (DRUG).
Who is sponsoring clinical trial NCT01511029?
This trial is sponsored by Knopp Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.